<DOC>
	<DOCNO>NCT00261313</DOCNO>
	<brief_summary>This study dose dense doxorubicin/cyclophosphamide ( AC ) follow paclitaxel ( Taxol ; T ) pegfilgrastim ( Neulasta ) darbepoetin alfa support adjuvant breast cancer setting .</brief_summary>
	<brief_title>ACCELERATE : Doxorubicin Cyclophosphamide Followed Paclitaxel With Pegfilgrastim Darbepoetin Alfa Support Treatment Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Breast cancer diagnosis nodepositive high risk node negative Estrogen receptor ( ER ) negative ER positive ( stage IIA , IIB IIIA ) disease . Metastatic breast cancer Clinically significant cardiac disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Doses dense chemotherapy</keyword>
	<keyword>Growth factor support</keyword>
	<keyword>Adjuvant Breast Cancer</keyword>
</DOC>